Nalan Utku

USPTO Granted Patents = 10 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 1.4

ph-index = 3

Forward Citations = 50(Granted Patents)

Location History:

Berlin, DE (2010 - 2016)
Luxembourg, LU (2017)
Dortmund, DE (2017 - 2019)
Bonn, DE (2018 - 2020)
Munich, DE (2024)

Company Filing History:

The Brigham and Women's Hospital, Inc.

4. 3 out of 832,812

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11892454 - Method for the diagnosis of etoposide prodrug treatable cancer (2024-02-06),

2. 10806745 - Analogues of etoposide for the treatment of tumours (2020-10-20),

3. 10183035 - Etoposide and prodrugs thereof for use in targeting cancer stem cells (2019-01-22),

4. 9889147 - Analogues of etoposide for the treatment of tumours (2018-02-13),

5. 9827261 - Etoposide and prodrugs thereof for use in targeting cancer stem cells (2017-11-28),

6. 9556271 - Anti-CEACAM1 recombinant antibodies for cancer therapy (2017-01-31),

7. 9399679 - Therapeutic anti-TIRC7 antibodies for use in immune related and other diseases (2016-07-26),

8. 7931901 - T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof (2011-04-26),

9. 7863418 - T-cell membrane protein (TIRC7) and peptides derived therefrom (2011-01-04),

10. 7794715 - Anti-TIRC7 antibodies in therapy of inflammatory diseases (2010-09-14),

Title: Nalan Utku: Innovator in Cancer Treatment

Introduction

Nalan Utku is a prominent inventor based in Berlin, Germany, known for her significant contributions to cancer treatment through innovative methods and compounds. With a total of 10 patents to her name, she has made remarkable strides in the field of oncology.

Latest Patents

Her latest patents include a method for the diagnosis of etoposide prodrug treatable cancer. This invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods involve analyzing carboxyelesterase 2 (CES2) expression in tumor samples as a predictive value for treatment success. Additionally, she has developed analogues of etoposide for the treatment of tumors, which are designed to address metastatic tumors and those that reduce organ function.

Career Highlights

Throughout her career, Nalan has worked with notable organizations such as Cellact Pharma GmbH and The Brigham and Women's Hospital, Inc. Her work has focused on advancing cancer therapies and improving patient outcomes through innovative research.

Collaborations

Nalan has collaborated with esteemed colleagues, including Steven R Gullans and Edgar L Milford, contributing to the advancement of cancer treatment methodologies.

Conclusion

Nalan Utku's innovative work in cancer treatment exemplifies her dedication to improving patient care through scientific advancements. Her contributions continue to influence the field of oncology and inspire future research.

This text is generated by artificial intelligence and may not be accurate.